Australia To Fund Mekinist, Xalkori But More Evidence Will Be Needed
This article was originally published in Scrip
Executive Summary
In another example of reimbursement agencies agreeing to pay for expensive new drugs in exchange for a commitment to provide more evidence of real clinical value, two major new anticancers from Novartis and Pfizer have been recommended for funding by the Australian Pharmaceutical Benefits Scheme under managed entry schemes. The agreements include a commitment to provide more convincing data with the possibility of a price cut if the terms of the schemes are not met.
You may also be interested in...
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.
EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants
The EU’s pharmacovigilance committee says that a review of the available evidence showed that in several cases, blood levels of immunosuppressants increased rapidly to toxic levels in patients who were taking the Pfizer drug.